UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 22, 2024 (March 19, 2024) |
ARCA biopharma, Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware | 000-22873 | 36-3855489 | ||
(State or Other Jurisdiction | (Commission File Number) | (IRS Employer | ||
|
|
|
|
|
10170 Church Ranch Way Suite 100 |
| |||
Westminster, Colorado |
| 80021 | ||
(Address of Principal Executive Offices) |
| (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (720) 940-2200 |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
| Trading |
|
|
Common |
| ABIO |
| The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On March 19, 2024, ARCA biopharma, Inc., a Delaware corporation (“ARCA”), entered into the First Amendment to Office Lease Agreement (the “Lease Amendment”) with Lotus Church Ranch, LLC (the “Landlord”), which amended that certain Office Lease Agreement, dated as of August 7, 2020, related to the Company’s headquarters in Westminster, Colorado (the “Lease”).
Under the Lease Amendment, the term of the Lease was extended an additional six (6) months through September 30, 2024 (the “Lease Extension”). Commencing on April 1, 2024, the minimum monthly rent shall be increased to $8,206.42. If the Company elects to stay in the property after the Lease Extension, it will pay rent month to month equal to 125% of the base rent paid in September 2024.
The foregoing description of the Lease Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Lease Amendment, a copy of which is attached as Exhibit 10.1 to this report and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number | Description | |
10.1 |
| |
104 | Cover Page Interactive Data File. The cover page XBRL tags are embedded within the inline XBRL document (contained in Exhibit 101). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
| ARCA biopharma, Inc. |
|
|
|
|
Date: | March 22, 2024 | By: | /s/ C. Jeffrey Dekker |
|
|
| Name: C. Jeffrey Dekker |